The cytomegalovirus treatment market is projected to grow from USD 273.3 million in 2025 to USD 494.0 million by 2035, at a CAGR of 6.1%. Valganciclovir for Cytomegalovirus Treatment will dominate with a 38.2% market share, while organ transplantations will lead the application segment with a 45.7% share.